{"id":54291,"date":"2023-02-27T23:06:45","date_gmt":"2023-02-27T22:06:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/"},"modified":"2023-02-27T23:06:45","modified_gmt":"2023-02-27T22:06:45","slug":"stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/","title":{"rendered":"Stoke Therapeutics to Participate at Upcoming March Investor Conferences"},"content":{"rendered":"
\n

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc.<\/a> (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences:\n<\/p>\n

<\/a><\/p>\n

\nCowen 43rd Annual Health Care Conference
\n
<\/b>Date: <\/b>Monday, March 6, 2023
\n
Time: <\/b>12:50 p.m. ET\n<\/p>\n

\n2nd Annual Needham Virtual Neuroscience Forum
\n
<\/b>Date: <\/b>Wednesday, March 15, 2023
\n
Time: <\/b>3:20 p.m. ET\n<\/p>\n

\nLive webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke\u2019s website at https:\/\/investor.stoketherapeutics.com\/<\/a>.\n<\/p>\n

\nAbout Stoke Therapeutics
\n
<\/b>Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke\u2019s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke\u2019s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke\u2019s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https:\/\/www.stoketherapeutics.com\/<\/a> or follow Stoke on Twitter at @StokeTx<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nStoke Investor Contact:<\/b>
Eric Rojas
\n
Vice President, Investor Relations
\n
IR@stoketherapeutics.com<\/a>
617-312-2754\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference Date: Monday, March 6, 2023 Time: 12:50 p.m. ET 2nd … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54291","6":"format-standard","7":"category-industry"},"yoast_head":"\nStoke Therapeutics to Participate at Upcoming March Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stoke Therapeutics to Participate at Upcoming March Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference Date: Monday, March 6, 2023 Time: 12:50 p.m. ET 2nd ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-27T22:06:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230227005745\/en\/736143\/21\/Stoke_Logo1_-_CMYK_50percent.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Stoke Therapeutics to Participate at Upcoming March Investor Conferences\",\"datePublished\":\"2023-02-27T22:06:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/\"},\"wordCount\":308,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005745\\\/en\\\/736143\\\/21\\\/Stoke_Logo1_-_CMYK_50percent.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/\",\"name\":\"Stoke Therapeutics to Participate at Upcoming March Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005745\\\/en\\\/736143\\\/21\\\/Stoke_Logo1_-_CMYK_50percent.jpg\",\"datePublished\":\"2023-02-27T22:06:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005745\\\/en\\\/736143\\\/21\\\/Stoke_Logo1_-_CMYK_50percent.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230227005745\\\/en\\\/736143\\\/21\\\/Stoke_Logo1_-_CMYK_50percent.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stoke Therapeutics to Participate at Upcoming March Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stoke Therapeutics to Participate at Upcoming March Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Stoke Therapeutics to Participate at Upcoming March Investor Conferences - Pharma Trend","og_description":"BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference Date: Monday, March 6, 2023 Time: 12:50 p.m. ET 2nd ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-27T22:06:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230227005745\/en\/736143\/21\/Stoke_Logo1_-_CMYK_50percent.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Stoke Therapeutics to Participate at Upcoming March Investor Conferences","datePublished":"2023-02-27T22:06:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/"},"wordCount":308,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230227005745\/en\/736143\/21\/Stoke_Logo1_-_CMYK_50percent.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/","name":"Stoke Therapeutics to Participate at Upcoming March Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230227005745\/en\/736143\/21\/Stoke_Logo1_-_CMYK_50percent.jpg","datePublished":"2023-02-27T22:06:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230227005745\/en\/736143\/21\/Stoke_Logo1_-_CMYK_50percent.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230227005745\/en\/736143\/21\/Stoke_Logo1_-_CMYK_50percent.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/stoke-therapeutics-to-participate-at-upcoming-march-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Stoke Therapeutics to Participate at Upcoming March Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54291"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54291\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}